BIOVECTRA
11 Aviation Avenue, Charlottetown, PE C1E 0A1
Canada
T: (866) 883-2872
E: solutions@biovectra.com
W: https://www.biovectra.com/
LinkedIn: https://www.linkedin.com/company/biovectra-inc-/
Twitter: https://twitter.com/BIOVECTRA

We care about making better therapeutics.

BIOVECTRA is a full-service CDMO specializing in the clinical-to-commercial-scale production of high-quality regulated APIs and intermediates, including biologics, synthetic small molecules, pDNA and mRNA, highly potent APIs, and bioreagents. Our teams leverage decades of expertise and a proven track record of excellence to optimize, adapt, and perfect innovative technologies and drug substance development approaches to deliver world-class solutions for pharmaceutical manufacturing.

• Over 50 years of pharmaceutical manufacturing experience
• Flexible, creative systems designed to deliver solutions quickly and efficiently
• Extensive regulatory expertise backed by long standing relationships with major regulatory bodies

Our Facilities

• 5 cGMP facilities in Atlantic Canada​
• 270,000+ sq ft manufacturing facility​
• 118,000 L of chemical reactor space​
• 64,000 L of fermentation bioreactor capacity
  Plus… a 36,000 sq ft Biomanufacturing and Vaccine Center (under construction with a planned completion date of Q3, 2023)

NEW!  BIOVECTRA Expands Manufacturing Capacity With Single-Use Microbial Fermentation Technology

BIOVECTRA is accepting projects at its manufacturing facility in Windsor, Nova Scotia, Canada, for its new, single-use biologics fermentation suite.

Containing 100 L and 1,000 L single-use fermenters, this state-of-the-art process train provides BIOVECTRA customers with several benefits including:

• greater flexibility
• faster turnaround times
• increased capacity utilization
• a decreased risk of contamination
• elimination of costly and time-consuming cleaning and sterilization between batches, which is essential with stainless-steel equipment